A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha 2b in patients with recurrent epithelial ovarian cancer

Author(s):
Dijkgraaf, E.M.; Santegoets, S.J.A.M.; Reyners, A.K.L.; Goedemans, R.; Wouters, M.C.A.; Kenter, G.G.; Erkel, A.R. van; Poelgeest, M.I.E. van; Nijman, H.W.; Hoeven, J.J.M. van der (0000-0003-1117-1959); Welters, M.J.P.; Burg, S.H. van der (0000-0002-6556-0354); Kroep, J.R.
Published
2015
Publication type
Article / Letter to editor
ovarian cancerinterleukin-6immunotherapychemoresistancetumor immunity
Date issued
2015-10-31
Language
English
Is part of
Annals of Oncology (2015), Vol. 26, no. 10, p. 2141-2149
hdl
1887/108018
doi
10.1093/annonc/mdv309